Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Condition(s):Thrombotic Thrombocytopenic PurpuraLast Updated:March 15, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Thrombotic Thrombocytopenic PurpuraLast Updated:March 15, 2024Recruiting
Condition(s):Anxiety; Anxiety, ExamLast Updated:November 29, 2023Recruiting
Condition(s):Thrombotic MicroangiopathiesLast Updated:March 4, 2024Not yet recruiting
Condition(s):Dermatitis, AtopicLast Updated:April 21, 2020Completed
Condition(s):Type 2 Diabetes Mellitus; ObesityLast Updated:August 30, 2023Completed
Condition(s):Primary CNS LymphomaLast Updated:February 9, 2024Recruiting
Condition(s):Dermatochalasis of EyelidLast Updated:November 1, 2023Completed
Condition(s):Aortic Dissection; Aneurysm, Aortic Arch; Aortic Pseudoaneurysm; Aortic Ulcer, Penetrating; Aortic Intramural HematomaLast Updated:October 11, 2023Active, not recruiting
Condition(s):Sickle Cell DiseaseLast Updated:November 4, 2020Completed
Condition(s):Acute Ischemic Stroke; Reperfusion; Large Vessel OcclusionLast Updated:September 28, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.